WHAT IS CLAIMED IS:

1. Use of a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of chronic lung allograft dysfunction in a subject.

2. The use of claim 1, wherein the chronic lung allograft dysfunction is bronchiolitis obliterans syndrome.

3. The use of claim 1 or claim 2, wherein the subject is a lung transplant recipient.

4. The use of claim 1 or claim 2, wherein the subject is a double lung transplant recipient.

5. The use of claim 2, wherein the subject suffers from Grade 0p, Grade 1, Grade 2, or Grade 3 bronchiolitis obliterans syndrome as determined by International Society for Heart and Lung Transplantation (ISHLT) criteria.

~~6. The use of claim 2, wherein the medicament is formulated to provide about a 10% or greater increase in FEV_1 at twelve weeks following the first administration of the medicament to the subject.~~

~~7. The use of any one of claims 1 to 6, wherein the JAK1 pathway inhibitor, or the pharmaceutically acceptable salt thereof, is a JAK1/2 inhibitor, or a pharmaceutically acceptable salt thereof.~~

~~8. The use of claim 7, wherein the JAK1/2 inhibitor is ruxolitinib, or a pharmaceutically acceptable salt thereof, or baricitinib, or a pharmaceutically acceptable salt thereof.~~

~~9~~6. The use of any one of claims 1 to ~~6~~5, wherein the selective JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is selective for JAK1 over JAK2, JAK3, and Tyk2.

~~10~~7. ~~T~~he use of claim ~~9~~6, wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

~~11~~8. The use of claim ~~9~~6, wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.

~~12~~9. Use of a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing the risk of bronchiolitis obliterans syndrome in a subject.

~~13~~10. The use of claim ~~12~~9, wherein the subject is a lung transplant recipient.

~~14~~11. The use of claim ~~12~~9, wherein the subject is a double lung transplant recipient.

~~15. The use of any one of claims 12 to 14, wherein the JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, is a JAK1/2 inhibitor, or a pharmaceutically acceptable salt thereof.~~

~~16. The use of claim 15, wherein the JAK1/2 inhibitor is ruxolitinib, or a pharmaceutically acceptable salt thereof, or baricitinib, or a pharmaceutically acceptable salt thereof.~~

~~17~~12. The use of any one of claims ~~12~~ 9 to ~~14~~11, wherein the selective JAK1 pathway inhibitor is selective for JAK1 over JAK2, JAK3, and Tyk2.

~~18~~13. The use of claim ~~17~~12, wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.

~~19~~14. The use of claim ~~17~~12, wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.

~~20~~15. Use of a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ~~-~~reducing the risk of lung re-transplantation in a subject.

~~21~~16. Use of a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing the risk of hospitalization in a subject, wherein the medicament is formulated to be administered to said subject in an effective amount and wherein said subject is (a) diagnosed with bronchiolitis obliterans syndrome; (b) has had a lung transplantation within 1 to 5 years prior to administering the selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, and (c) does not have a decrease in FEV_1 attributable to a cause other than bronchiolitis obliterans syndrome.

17. Use of {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1Hpyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of bronchiolitis obliterans syndrome in a subject.

18. The use of claim 18, wherein the pharmaceutically acceptable salt is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.